

# TABLE OF CONTENTS

October 26, 2009

No. 2161

## BUSINESS

- 1 Biogen Idec Japan Aims at 50% Share in Market for IFN- $\beta$
- 2 Rasilez May Become Blockbuster: T. Rosenberg, Novartis
- 2 Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
- 3 Nat'l Univ. Hospitals Plans to Start Joint Purchasing in FY2010
- 3 Hokkaido Univ. Hospital to Increase Direct Purchase of Drugs
- 4 Cravit Remains No. 1 on Both HP, GP Markets: Rep Track Survey
- 4 **TOPICS**
  - Otsuka Holdings Receives 2009 Investor in France Award
  - Kringle Pharma Receives Grand Prix of the 6th Japan Bio-Venture Award
- 6 Global Pharmaceutical Market to Grow 4-6% in 2010: IMS Health
- 6 **BUSINESS NEWS IN BRIEF**
  - MTPC Reorganizes US Group Companies
  - Mediscience: Sales Up, Profits Down
  - Total Number of MRs Up 4.2% to 58,400
  - Astellas, BI Settle Flomax Patent Dispute with Impax

## REGULATORY

- 8 *Koroshō* to Stop Use of Add'l ¥85.4 Bil. in FY2009 Supplementary Budget
- 8 NHI Price Revision Rate, Policy to Be Proposed by Panel under Health Minister
- 9 JMA Demands Increases in Medical Fees
- 9 Forum Attendants Express Concern about Rising Dispensing Fees
- 10 No Mention Made on Development of Drugs at *Koroshō* Policy Conference
- 10 New Administration Route Approved for Temodal
- 11 **REGULATORY NEWS IN BRIEF**
  - Onglyza Approved for Type 2 Diabetes in Europe
  - sNDA Submitted to FDA for Clonigel for ADHD: Shionogi, Sciele
  - Restrictions Lifted for Isentress for HIV Treatment-Naive: Banyu

## R&D

- 12 Shionogi Allies with UK Universities, Bioventures for Drug Discovery
- 12 Life Science Degrades to 2nd Place in Priority Science and Technology Ranking

## 13 R&D NEWS IN BRIEF

- Oncolys Licenses Anticancer Agent from Astellas
- BioWa, Lonza to Offer Potent New Cell Line for Antibody Production
- ePRO's Advantages Outlined by Dr Raymond
- Lantus Shows Superior Efficacy-Dose Ratio over Detemir: sanofi-aventis

## COMMENTARY

- 14 **Maurer's Healthcare Insight (114)**
  - Can Bioventures Succeed in Japan?: P. Reed Maurer

## GENERICS

- 18 *Koroshō* to Base Requirements for Premium for Generics on Their Volume Dispensed
- 18 New Gov't Will Continue to Promote Use of Generics: Mr Isobe
- 19 Biosimilars to Save 8.1 Billion Euro by 2020 in Germany
- 19 **Statistics**
  - Sales of OTC Drugs Increase in Aug. for the First Time in 3 Months: Crecon

## MEDICAL DEVICES

- 20 4 Medical Devices Recommended for Approval

## 20 NEW PRODUCTS

- Yakuban Tape 60 mg to Be Launched in December

## MEDICAL FACILITIES & NURSING CARE

- 21 **32nd JSH Annual Scientific Meeting**
  - Coadministration of ARB and CCB More Effective Than Fixed-Dose Combination Drug: Dr Ishimitsu
  - Coadministration of ARB and Diuretic Causes No Abnormalities in Patients with Hypertension and DM
  - Various Combination Therapies Should Be Considered to Lower Blood Pressure: Dr Shimada
- 22 Findings from Evista's 3-Year PMS Reported
- 23 Blood Sugar Control Improved in Diabetes Patients Switching to Liraglutide: Novo Nordisk
- 23 Incretin Therapy Suitable for Japanese Patients with Diabetes: Dr Seino